Henlius Biotech wins shareholder approval for Star dual listing

By Jonathan Breen
31 Mar 2020

Hong Kong-listed Shanghai Henlius Biotech got the go ahead from its controlling shareholders on Monday for a secondary flotation on China’s Star Market.

The biopharmaceutical company is a subsidiary of Shanghai Fosun Pharmaceutical, which is controlled by Fosun International. Both are HKEX-listed companies and hold a combined indirect 53% stake in Shanghai Henlius.

The subsidiary listed on the HKEX in September last year through a HK$3.21bn ($414m) spin-off by Fosun ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial